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IDH1 mutation and classification of high grade gliomas 
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Abstract  
 
WHO grading of human brain tumors extends beyond a strictly histological grading system by 
providing a basis predictive for the clinical behavior of the respective neoplasm. For example, patients 
with glioblastoma WHO grade IV usually show a less favorable clinical course and receive more 
aggressive first-line treatment than patients with anaplastic astrocytoma WHO grade III. Here we 
provide evidence that the IDH1 status is more prognostic for overall survival than standard histological 
criteria that differentiate high-grade astrocytomas. We sequenced the isocitrate dehydrogenase 1 
gene (IDH1) at codon 132 in 382 patients with anaplastic astrocytoma and glioblastoma from the 
NOA-04 trial and from a prospective translational cohort study of the German Glioma Network. 
Patients with anaplastic astrocytomas carried IDH1 mutations in 60%, and patients with glioblastomas 
in 7.2%. IDH1 was the most prominent single prognostic factor (RR=2.7; 95%-CI 1.6 to 4.5) followed 
by age, diagnosis and MGMT. The sequence from more favorable to poorer outcome was 1) 
anaplastic astrocytoma with IDH1 mutation, 2) glioblastoma with IDH1 mutation, 3) anaplastic 
astrocytoma without IDH1 mutation and 4) glioblastoma without IDH1 mutation (p<0.0001). In this 
combined set of anaplastic astrocytomas and glioblastomas both, IDH1 mutation and IDH1 expression 
status were of greater prognostic relevance than histological diagnosis according to the current WHO 
classification system. Our data indicate that much of the prognostic significance of patient age is due 
to the predominant occurrence of IDH1 mutations in younger patients. Immunohistochemistry using a 
mutation-specific antibody recognizing the R132H mutation yielded similar results. We propose to 
complement the current WHO classification and grading of high-grade astrocytic gliomas by the IDH1 
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Introduction 
 
WHO classification and grading of human brain tumors is a dynamic classification system undergoing 
regular updating. Classification of brain tumors relies on the presumed recognition of cell lineages 
giving rise to specific tumor entities. WHO classification of brain tumors distinguishes diffuse 
astrocytomas and glioblastomas among astrocytic tumors on grounds of their predominant astrocytic 
differentiation. Grading of astrocytomas relies on an evaluation of anaplasia, dedifferentiation and 
malignancy. The WHO criteria for anaplasia in diffuse astrocytomas include increased cellularity, 
distinct nuclear atypia and mitotic activity. Glioblastoma are defined as anaplastic, cellular gliomas 
composed of poorly differentiated, often pleomorphic astrocytic tumor cells with marked nuclear atypia 
and brisk mitotic activity. Prominent microvascular proliferation and/or necrosis are essential 
diagnostic features. Malignancy, however, extends beyond the term of anaplasia because it evokes 
clinical parameters such as tumor recurrence and clinical outcome. The WHO classification of brain 
tumors has emphasized a malignancy scale underlying its brain tumor grading rather than a purely 
histology based algorithm [11]. Thus, the identification of glioma subgroups exhibiting significant 
differences in clinical outcome within an established WHO tumor entity would necessitate an 
adjustment of the WHO grading system. At present the distinction between anaplastic astrocytoma 
and glioblastoma has clinical implications regarding the choice of treatments with more aggressive 
treatments for glioblastoma. Hence, novel prognostic factors may influence clinical decision making 
regarding treatment. 
Cytosolic isocitrate dehydrogenase 1 (IDH1) mutations were initially detected in a fraction of 
glioblastomas [14] followed by the observation that they are present in the majority of diffuse 
astrocytomas, oligodendrogliomas and mixed oligoastrocytomas of WHO grades II and III [1, 7, 9, 22, 
26]. Consistently, the IDH1 mutation rate is also high in secondary glioblastoma developing from 
previously diagnosed astrocytoma. While approximately 70% of the diffuse astrocytomas and 
secondary glioblastomas carry IDH1 mutations, this alteration is observed in less than 10% of primary 
glioblastoma. These observations so far provide the strongest molecular evidence for different origins 
of primary glioblastoma and secondary glioblastoma [13]. On the other hand, the occurrence of IDH1 
mutations in the majority of both diffuse astrocytomas and oligodendroglial tumors requires 
reevaluation of the relation between these tumor entities. This contrasts findings suggesting a 
separation of astrocytic and oligodendroglial tumors on grounds of characteristic genomic alterations, 
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mainly TP53 mutations in diffuse astrocytoma and combined 1p/19q losses in oligodendroglial tumors 
[10]. These observations indicate that IDH1 mutational status may be a marker distinguishing tumor 
lineages and point to a common origin of diffuse astrocytoma including secondary glioblastomas and 
oligodendroglial tumors. Determination of IDH1 mutation frequency in these tumors was followed by 
clinical analyses revealing that this mutation constitutes a favorable prognostic factor for both patients 
with anaplastic astrocytoma [25] and glioblastoma [23]. In fact, the prognostic power of presence or 
absence of this mutation exceeded that of other markers such as MGMT promoter methylation status. 
The role of IDH1 mutations in tumorigenesis is under intense investigation. These mutations, 
which nearly always affect codon 132 in gliomas and which nearly always occur in a heterozygous  
manner leaving one parental allele unaffected, strongly compromise the ability of the enzyme to 
decarboxylate isocitrate to α-ketoglutarate and to generate NADPH [9, 26]. In contrast, mutated IDH1 
protein gains a novel function enabling the conversion of α-ketoglutarate to 2-hydroxyglutarate in a 
NADPH-consuming manner [5, 21]. While 2-hydroxyglutarate appears to increase the levels of 
reactive oxygen species, its role for tumor development is not clear. The mutation causes reduced 
catalytic generation of α-ketoglutarate which combined with its additional consumption due to the 
gained function may inhibit prolyl hydroxylases thereby resulting in activation of the transcription 
factor, hypoxia-inducible factor (HIF) [27].  
The objective of our present study was to investigate whether the IDH1 mutation status provides 
an essential contribution to delineate the individual prognosis in patients with anaplastic astrocytoma 
or primary glioblastoma, respectively, and to assess whether the WHO grading system should be 
amended in this regard. For this purpose, we assembled a large cohort of anaplastic astrocytoma and 
glioblastoma patients who were treated and prospectively followed up within the NOA-04 trial or the 
German Glioma Network. The prognostic impact of IDH1 mutation and MGMT promoter methylation in 
these patients was assessed in relation to the histological classification. Based on our results, we 
propose a refinement of the current WHO classification of high-grade astrocytic gliomas that considers 
the IDH1 mutation status in addition to the classic histological parameters.  
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Material and Methods 
 
Patients, clinical and molecular data and immunohistochemistry 
A group of 382 patients with anaplastic astrocytoma (n=145) or primary glioblastoma (n=237) forms 
the basis of this study. Clinical and molecular data are derived from 94 patients with anaplastic 
astrocytoma treated in the NOA-04 trial [25] and from 51 patients with anaplastic astrocytoma and 237 
patients with glioblastoma included in the prospective translational cohort study of the German Glioma 
Network (GGN) [23]. None of the glioblastoma patients in this study had a history of previous 
manifestation as diffuse astrocytoma WHO grade II or anaplastic astrocytoma and all cases from both 
studies were centrally reviewed by the same neuropathologist (T.P.) at the German Brain Tumor 
Reference Center of the German Society for Neuropathology and Neuroanatomy (DGNN) according to 
the revised WHO 2000 and 2007 classifications [11], assuring identical histological classification and 
grading. Data from both studies were compiled in a joint database and centrally analyzed. Data from 
the NOA-04 trial [25] and data from the ongoing translational study of the GGN [23] have been 
published previously.  
The methods and conditions for determining the mutational status of IDH1 by direct 
sequencing of PCR products has been described previously [23, 25]. Methods and conditions for 
detecting the IDH1R132H mutation by IHC with mouse monoclonal antibody H09 (Dianova, catalog 
number DIA H09, Hamburg, Germany) on an automated immunostainer (BenchMark, Ventana 
Medical Systems, Tuscon, AZ, USA) have been described in detail elsewhere [3-4]. Analysis for 
MGMT promoter methylation by methylation-specific PCR (MSP) was performed as previously 
described [23, 25]. 
Patients in this study were recruited between January 2004 and August 2008. The GGN data 
were used with a cut-off value for last information of December 31st 2009. The extent of resection was 
assessed by early (<72 hours) magnetic resonance imaging (MRI) or computed tomography (CT) but 
was not centrally reviewed. Complete resection was scored whenever no residual tumor was detected; 
subtotal resection corresponded to removal of 50% to 99% of the tumor and partial resection to 
removal of less than 50% of the tumor. Overall survival (OS) was the primary endpoint of most 
analyses which is most appropriate for this retrospective analysis of pooled patients from a clinical trial 
(NOA-04) and a large cohort study (GGN). Data on postsurgical first-line treatment and treatment at 
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The association of clinical data and molecular markers were tested by χ2-test and Fisher’s exact test. 
Predictive values, sensitivity and specificity with 95%-CI were determined to assess the validity of IHC 
to IDH1 mutations in comparison to DNA sequencing as gold standard. OS, the primary endpoint, was 
calculated from the day of first surgery until death or end of follow up. Logrank test was used to 
compare outcome data. Cox regression models were fitted to assess the independent impact of the 
IDH1 mutation (mutated vs. wild type), adjusting for age (>60 vs. ≤ 60), diagnosis (anaplastic 
astrocytoma vs. glioblastoma), MGMT-status (methylated yes vs. not methylated), and extent of 
resection (total vs. not total). Interaction between IDH1 mutation and histological diagnosis as well 
MGMT promoter methylation and histological diagnosis were evaluated in multivariate models. Data 
were analyzed by PASW Statistics 18 (Version 18.0.0) and StatXact-8 (Cytel Studio Version 8.0.0). 
 




Patient characteristics are given in table 1. As expected, patients with anaplastic astrocytoma were 17 
years younger (median) than patients with glioblastoma, had better performance status, experienced 
somewhat less radical surgery and less frequently received combined modality treatment as first-line 
treatment. Hence any analysis of prognostic factors needed adjustment for these imbalances in order 
to separate the contribution of each single factor. 
 
IDH1 sequencing and immunohistochemical data 
IDH1 mutations were detected in 104 of 382 high grade malignant astrocytic gliomas. In 145 
anaplastic astrocytomas we found 87 mutations (60.0%) with 78 of the R132H, 6 of the R132C, 2 of 
the R132S and 1 of the R132G types. In 237 glioblastomas we found 17 IDH1 mutations (7.2%) which 
were all of the R132H type. All mutations in anaplastic astrocytomas and glioblastomas were 
heterozygous. IDH2 mutations were analyzed in 365 patients of the 382 patients. Only a single 
glioblastoma patient carried an IDH2 R172K mutation. 
A total of 197 cases consisting of 80 anaplastic astrocytomas and 117 glioblastomas were 
analyzed by IHC with monoclonal antibody H09 specific for mutant IDH1 protein encoded by the 
IDH1R132H mutation. We detected mutant IDH1 protein in 40 anaplastic astrocytomas and in 19 
glioblastomas. Seven mutations which were recognized by sequencing were not detected by the 
mutation-specific antibody. These included five patients with four R132C and one R132S mutations 
which were not recognized by the mutation-specific antibody and two patients which were sequenced 
with the IDH1R132H mutation but did not exhibit antibody binding. On the other hand three cases 
were detected with the antibody but had escaped initial sequencing due to a signal below threshold. 
However, re-sequencing confirmed the mutation. Thus all IHC-positive cases were confirmed by 
sequencing. 
Hence, the positive predictive value (PPV) of IHC for IDH1 R132H mutations is 100 % (95%-
CI 93.4% to 100%), while the negative predictive value (NPV) of a negative IHC for excluding IDH1-
mutations is 94.9 % (95%-CI 89.8% to 97.4%). Sensitivity is 89.4% (95%-CI 79.4% to 95.6%) and 
specificity 100% (95%-CI 97.2% to 100%). This implies that IHC is highly predictive of the sequencing 
result and can therefore be used as a very powerful surrogate marker of the IDH1 sequence status. 
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MGMT promoter methylation  
The MGMT promoter methylation status was determined in 338 patients including 105 anaplastic 
astrocytoma and 233 glioblastoma patients. Among anaplastic astrocytoma patients 58 exhibited 
MGMT promoter methylation while 47 did not. Among glioblastomas, 110 exhibited a methylated 
MGMT promoter while 123 did not. MGMT and IDH1 status in the 105 anaplastic astrocytomas and 
233 glioblastomas are given in table 1. This table also provides the relationships between molecular 
findings for both genes and patient age groups. It is noteworthy that MGMT promoter methylation was 
more frequent in IDH1 mutated tumors (69%, 53/77) than in wild type-IDH1-tumors (44%, 115/261), 
irrespective of the histological diagnosis (p=0.0001). 
 
Survival (univariate analysis) 
Figure 1 shows OS estimates in a univariate breakdown regarding the main factors diagnosis, age, 
IDH1 status and MGMT status. Patients with anaplastic astrocytoma lived significantly longer than 
patients with glioblastoma (p<0.0001) (figure 1 a). The median OS was 42.5 months (95%-CI 31.9 to 
53.2) for anaplastic astrocytoma and 13.6 months (95%-CI 11.6 to 15.6) for glioblastoma. Patients 
with IDH1 mutations lived longer than patients without (p<0.0001) (figure 1b), Patients with MGMT 
promoter methylation lived longer than patients without (p<0.0001) (figure 1c) and furthermore, we 
confirmed younger age at diagnosis as a significant prognostic factor associated with longer OS 
(p<0.0001) (figure 1d). When we calculated the relative risks (RR) for these pair-wise comparisons, we 
found the largest risk for IDH1 wild type versus mutant (RR=5.1; 95%-CI 3.5 to 7.5) followed by 
glioblastoma versus anaplastic astrocytoma (RR=3.4; 95%-CI 2.5 to 4.6), old versus young age 
(RR=3.3; 95%-CI 2.6 to 4.3) and MGMT non-methylated versus methylated (RR=2.3 ; 95%-CI 1.7 to 
3). These findings are already indicative of a strong prognostic contribution of the IDH1 mutation 
status. However, these univariate contrasts are confounded by the unbalanced compositions of the 
groups. Hence, multivariate modeling is required to adjust for these effects.  
 
Survival (multivariate analysis) 
Figures 2-4 provide insights into the multivariate structure of the survival data. For this purpose, we 
separated the OS estimates in subgroups using two (or three) main factors. Co-evaluation of 
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diagnosis and MGMT status showed that both factors contribute to prognosis. MGMT splits the cohort 
into the most favorable clinical course for 47 anaplastic astrocytoma patients with MGMT promoter 
methylation, followed by 58 anaplastic astrocytoma patients without MGMT promoter methylation, 
followed by 110 glioblastoma patients with and trailed by 123 glioblastoma patients without MGMT 
promoter methylation (figure 2a). There is also an indication that the prognostic split associated with 
MGMT is slightly more pronounced in patients with glioblastoma compared to patients with anaplastic 
astrocytoma (see below). 
Co-evaluation of diagnosis and age indicates that both factors contribute to prognosis. 
Anaplastic astrocytoma patients aged 60 years or younger had the most favorable clinical course. The 
poorest survival occurred in glioblastoma patients older than 60 years. The age-effect seems to be 
more pronounced among anaplastic astrocytoma patients (figure 2b). 
Co-evaluation of histological diagnosis and IDH1 status showed that both factors contribute to 
prognosis. The most favorable OS was found in 87 anaplastic astrocytoma patients with IDH1 
mutation, followed by 17 glioblastoma patients with IDH1 mutation (p=0.014). The difference between 
the 17 glioblastoma patients with IDH1 mutation and 58 anaplastic astrocytoma patients without IDH1 
mutation was not significant (p=0.222). However, the Kaplan-Meier plots indicate a trend towards an 
inferior OS for patients with anaplastic astrocytoma patients without IDH1 mutation. These patients 
showed a longer OS than 220 glioblastoma patients without IDH1 mutation (p=0.003). The differences 
in OS across the whole cohort were highly significant (p<0.0001) (figure 3a). The separation of these 
four groups became even more prominent when PFS was analyzed instead of OS (figure 3b), but, as 
indicated above, PFS may not be an appropriate endpoint for a pooled analysis of a clinical trial where 
single modality treatment was the rule (NOA-04) and a cohort where single modality treatment was 
more likely given to patients with a more malignant tumor with less favorable prognostic factors 
(GGN). 
An analysis restricted to patients aged 60 years or younger again showed best OS in 78 
anaplastic astrocytomas with IDH1 mutation. Worst outcome was seen in 96 glioblastoma patients 
without IDH1 mutation (p<0.0001) (figure 3c). If we restricted the analysis to patients older than 60 
years, we find IDH1 mutations only rarely (N = 2 for glioblastoma, N = 9 for anaplastic astrocytoma) 
and these curves are not shown. However, we found that there was no apparent prognostic difference 
for anaplastic astrocytoma and glioblastoma patients without IDH1 mutation (p=0.457) (figure 3d). 
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Hence, elderly anaplastic astrocytoma patients without IDH1 mutation seem to have the same poor 
prognosis as glioblastoma patients. 
Co-evaluation of IDH1 and MGMT status revealed that MGMT permits to separate the prognostic 
difference by IDH1 mutations further. However, patients with IDH1 mutation performed better than 
patients without IDH1 mutation irrespective of MGMT status. Patients without IDH1 mutation but with 
MGMT promoter methylation fared worse and poorest survival was seen in patients showing neither 
IDH1 mutation nor MGMT promoter methylation (figure 4).  
Figure 5 shows the co-evaluation of the three main factors diagnosis, IDH1 and MGMT status. 
Clearly the dominant prognostic factors are related to the molecular status. There is a very poor 
prognostic group without IDH1 mutation and with unmethylated MGMT at one end of the spectrum 
(with few long-term survivors) and a small but very favorable group of IDH1 mutant and MGMT 
methylated patients (among whom long-term survival seems frequent). In most of the four groups, 
WHO diagnosis seemed to retain a small influence on OS. Among patients without IDH1 mutation and 
without MGMT promoter methylation, the 28 patients with anaplastic astrocytoma fared better 
(p=0.0012) than the 118 with glioblastoma (figure 5a). There was no significant difference (p=0.1824) 
in survival between 17 anaplastic astrocytoma and 98 glioblastoma patients without IDH1 mutation 
and with MGMT promoter methylation (figure 5b). Similarly, 41 anaplastic astrocytoma patients with 
IDH1 mutation and with MGMT promoter methylation did not live significantly longer (p=0.3534) than 
12 glioblastoma patients with the same molecular findings (figure 5d). The group defined by patients 
with IDH1 mutation and without MGMT promoter methylation included only 19 anaplastic astrocytoma 
and 5 glioblastoma patients and, therefore, was too small to yield conclusive results (figure 5c).  
 
Multivariate modeling  
Multivariate modeling was undertaken to estimate the RR for age, extent of resection, diagnosis, IDH1 
mutation status and MGMT status. The results for the main effects are given in table 2. IDH1 mutation 
was the dominant prognostic factor with a RR of 2.7 (95% CI 1.6 to 4.5). Histology and MGMT status 
were also prominent with RR of 2.2 respectively. Since RR can be multiplied, it becomes evident that 
this implies a very powerful system spanning a RR range of about 13 in total (2.7 x 2.2 x 2.2). 
Finally, in a sensitivity analysis, we also introduced two interaction terms into the main effects model. 
The model fit (i.e. log-likelihood) improved significantly. This model provides an indication that the 
IDH1 effect is quantitatively more pronounced in anaplastic astrocytoma (anaplastic astrocytoma: 
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RR=4.1 glioblastoma: RR=1.8) while the MGMT effect is more pronounced in glioblastoma (anaplastic 
astrocytoma: RR=1.3; glioblastoma: RR=2.5). 
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Discussion 
 
Classification and grading of high-grade astrocytic gliomas according to WHO is accompanied by a 
considerable interobserver variation [19]. Reasons are guidelines allowing for subjective interpretation. 
On the one hand, this may be due to a subjective interpretation of borderline histological features by 
different neuropathologists. On the other hand, malignant gliomas are regionally heterogeneous 
tumors and incomplete tissue sampling thus may lead to the underestimation of a tumor`s true 
malignancy grade when important histological features of anaplasia are restricted to focal areas and 
not represented in the evaluable tissue specimens. Molecular analyses are expected to reduce 
diagnostic interobserver variation due to providing clear yes/no answers in many instances and 
detecting molecular changes present in all tumor cells, thereby reducing the problems of subjectivity in 
histological assessment and incomplete tissue sampling. In the present study we focus on the role of 
the IDH1 status in assisting classification and grading of anaplastic astrocytomas and glioblastomas. 
The data set analyzed here was obtained by joining the primary data sets of the anaplastic 
astrocytoma patients treated within the NOA-04 randomized phase III trial [25], the glioblastoma 
cohort of the GGN [23], and a new subset of anaplastic astrocytomas from the GGN. In our series 
87/145 (60%) anaplastic astrocytomas and 17/137 (7.2%) glioblastomas carried a mutation in IDH1. 
The frequency of IDH1 mutations in anaplastic astrocytomas in our series is within the spectrum 
described in previous series ranging from 52% [9] to 78% [22]. The frequency of IDH1 mutation 
detected in glioblastomas has generally been reported to range below 10% in primary glioblastoma [1, 
9, 22, 26]. 
The impact of IDH1 mutations on clinical outcome has been demonstrated in prospective 
clinical studies including anaplastic astrocytomas and glioblastomas [20, 23, 25]. It has also been 
detected in various retrospective series including diffuse gliomas of WHO grades II, III and IV recently 
reviewed [15]. There is consensus on patients with IDH1 mutations performing better than those 
without [6, 9, 14, 17, 26]. Our data provide compelling evidence that the IDH1 status separates 
anaplastic astrocytomas and glioblastomas in two sub-entities each with significantly different clinical 
outcomes. Further, our data indicate a close clinical and biological relation of anaplastic astrocytomas 
and glioblastomas with IDH1 mutation versus anaplastic astrocytomas and glioblastomas without 
IDH1 mutations. The sequence from more favorable to poorer outcome was 1) IDH1 mutant anaplastic 
astrocytoma, 2) IDH1 mutant glioblastoma, 3) IDH1 wild type anaplastic astrocytoma and 4) IDH1 wild 
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type glioblastoma, respectively. The missing significance between groups 2 and 3 (p=0.222) might be 
due to the low number of patients with IDH1 mutant glioblastoma (n=17).  The prognostic relevance of 
IDH1 status in comparison with histopathological evaluation of high-grade astrocytomas is 
demonstrated in figures 1a and b and figure 5 and particularly in the multivariate modeling result  
Using the IDH1 mutation status as a separator to this predefined set of tumors, we were able 
to separate two patient groups with even more pronounced differences in median OS than those 
stratified according to conventional histological features. Thus, IDH1 analysis in this set of tumors is a 
more powerful prognostic marker than current WHO classification and grading for high-grade 
astrocytomas. Notably, IDH1 wild type anaplastic astrocytoma patients demonstrated not only shorter 
OS when compared to IDH1 mutant anaplastic astrocytoma patients but even survived shorter than 
patients with IDH1 mutant glioblastoma. 
Apart from the WHO diagnosis, patient age has been established as a powerful parameter for 
the prognosis of patients with anaplastic astrocytomas and glioblastomas [2]. Therefore, we also 
examined the relationship between IDH1 status and patient age. Analysis in patients aged 60 years or 
younger or over 60 revealed that in the younger age group, anaplastic astrocytoma patients without 
IDH1 mutations exhibited OS very similar to that of glioblastoma patients with IDH1 mutations (figure 
3c). Importantly, in patients over 60 years the absence of IDH1 mutation in anaplastic astrocytoma 
was indicative of poor OS that was similar to the OS of older patients with IDH1 wild type glioblastoma 
(Figure 3c). This may be of relevance for treatment decisions. 
A yet unsolved issue relates to the impact of IDH2 mutation on OS. So far, none of the 
previous series provided reliable data on the clinical relevance of IDH2 mutations alone [20]. IDH2 
mutations occur infrequently in astrocytic gliomas. In a large series including astrocytomas, 
oligodendrogliomas and oligoastrocytomas, the frequency of IDH2 mutations was 3.1%. Of note, IDH2 
mutations clustered in patients with oligodendroglial tumors but were found in less than 1% of 
astrocytomas [7]. We examined 132 anaplastic astrocytoma patients and 233 glioblastoma patients 
from the present series for IDH2 mutation in codon 172 and detected only a single R172K mutation in 
a glioblastoma patient. Because IDH2 mutations are so rare in anaplastic astrocytomas and 
glioblastomas, this molecular alteration was not further considered in the clinical correlations 
performed in the present study. 
MGMT promoter methylation status has been demonstrated as a powerful prognostic and 
predictive marker for patients with glioblastomas [8, 24]. Its relevance was confirmed in our series to 
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be independent of the IDH1 status (figure 2a, 5). For all four groups, stratified for diagnosis and 
presence or absence of IDH1 mutation, OS was longer in patients with MGMT promoter methylation. 
These differences were significant for glioblastomas with or without IDH1 mutation, and for anaplastic 
astrocytomas with IDH1 mutation. In contrast, the MGMT status was not associated with differential 
survival in anaplastic astrocytomas without IDH1 mutation. Interestingly, the rate of patients with 
MGMT methylation was higher in both anaplastic astrocytomas and glioblastomas with IDH1 mutation 
than in anaplastic astrocytomas and glioblastomas without IDH1 mutation. Upon sorting our series of 
338 patients into four groups defined by combined IDH1 and MGMT status, it became evident that the 
histological distinction between anaplastic astrocytomas and glioblastomas had only a moderate effect 
on OS (figures 5a – 5d). Noteworthy is the very similar gradient of the curves for both histological 
diagnoses within each group. This analysis underscores the importance of combined IDH1 and MGMT 
analysis to predict survival in these patients. 
We recently developed a monoclonal mouse antibody (mIDH1R132H/ clone H09) to mutant 
IDH1 protein of the R132H type [3-4]. The R132H mutation constitutes more than 90% of the IDH1 
mutations seen in gliomas [7]. Therefore, we performed immunohistochemistry with this antibody on 
197 tumors of our series, which revealed high positive and negative predictive values of H09 IHC for 
detecting IDH1 mutation, thus corroborating this method as a surrogate approach to DNA sequencing. 
Representative data for IHC with mouse monoclonal antibody H09 is shown in figure 6. Interestingly, 
we detected in three samples mutant IDH1 protein of the R132H type that showed no IDH1 mutation 
by initial sequencing. However, these IDH1 mutations were confirmed by re-sequencing. On the other 
hand, two IDH1 R132H mutations were not detected by the mIDH1R132H/clone H09 antibody. These 
findings show that both methods do not have a 100% detection rate but that detection rate is 
comparable.   
Based on the presented data we propose to consider a refinement of the current WHO 
classification and grading system for anaplastic astrocytomas and glioblastomas by subdividing each 
tumor entity into two molecularly and clinically distinct subgroups according to the IDH1 mutation 
status. This implies that this molecular parameter will become part of the tumor classification and thus 
needs to be determined on a regular basis. In detail, IDH1 mutant anaplastic astrocytomas should be 
separated from IDH1 wild type anaplastic astrocytomas, and likewise, glioblastomas with and without 
IDH1 mutation should be distinguished. It remains to be seen whether further molecular subdivision of 
glioblastomas according to the MGMT promoter methylation status will be applicable in the routine 
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diagnostic setting. In contrast to the technically simple and reliable detection of IDH1 mutations by 
DNA sequencing or immunohistochemistry, current methods for the molecular analysis of MGMT 
promoter methylation are technically more sophisticated, difficult to standardize, and thus suffer from 
considerable interlaboratory variability [15]. We expect an extended sub-classification of anaplastic 
astrocytomas and glioblastomas to be of immediate clinical impact. For example, our data clearly 
indicate that patients with IDH1 wild type anaplastic astrocytomas have poor clinical outcome. Thus, 
one could consider treating these patients more aggressively with first-line combined 
radiochemotherapy corresponding to the current standard of care for glioblastoma treatment. On the 
other hand, the rare IDH1 mutant primary glioblastomas may require less aggressive first-line 
treatment similar to that usually administered to anaplastic astrocytoma patients, that is, either 
radiotherapy or alkylating chemotherapy, but no combined modality treatment [25]. As IDH1 mutant 
glioblastomas usually affect younger patients and are associated with a higher likelihood of long-term 
survival, a less aggressive up-front treatment may be beneficial also in terms of reducing treatment-
associated neurotoxicity in these patients. It is not yet clear whether anaplastic astrocytomas without 
IDH1 mutation generally should be considered as underdiagnosed glioblastomas. While such an 
approach would yield a tighter correlation of diagnosis and OS than the current procedure, it does not 
account for the still better OS of anaplastic astrocytoma patients without IDH1 mutation than 
glioblastoma patients without IDH1 mutations. We also assume that our data will have major impact 
on reporting results from clinical trials and on the study designs for novel trials focusing on anaplastic 
astrocytomas and glioblastomas. The circumstance that the presence of IDH1 mutations is the 
strongest indicator for more favorable clinical outcome will make it inevitable to determine this 
parameter in order to test the influence of the experimental treatment applied. Furthermore, this 
molecular parameter likely will have an impact on the inclusion criteria of future trials. 
How could the WHO classification be developed in the future with regard to the optimal prognostic 
and clinically most helpful stratification of patients with high-grade astrocytic gliomas? There are 
several possibilities for this separation, such as the simple addition of the IDH1 status to the 
histological diagnosis to indicate that the respective tumor is associated with a more or less favorable 
clinical course. A more radical approach would be to disregard necrosis and microvascular 
proliferation as the basis for distinction between anaplastic astrocytomas and glioblastomas, and 
substitute these histological parameters by the IDH1 mutation status, that is high-grade astrocytic 
tumors with IDH1 mutation would be termed anaplastic astrocytomas while all high-grade astrocytic 
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tumors without IDH1 mutation would be termed glioblastomas. Such a procedure would result in a 
significantly tighter association of grading with clinical course and, therefore, would better suit the 
intention of glioma grading to provide a prognostically meaningful stratification that may guide the 
postoperative treatment. It would emphasize on biological properties inherent of distinct tumor cell 
lineages, i.e., astrocytoma deriving from a tumor precursor cell characterized by IDH1 mutation. 
However, it would also break with a long and well received tradition of purely histological grading by 
devaluating the prognostic importance of necrosis or microvascular proliferation. In fact, this approach 
would miss some prognostically relevant information, as indicated by the survival differences between 
anaplastic astrocytomas and glioblastomas within the group of IDH1 wild type tumors. IDH1 mutation 
is frequent in secondary glioblastomas derived by progression from astrocytomas. It has been 
suggested that IDH1 mutant primary glioblastoma in fact represent secondary glioblastoma that 
rapidly evolved from lower grade precursor tumors and thus have not been diagnosed before [13]. 
Thus, secondary glioblastomas and IDH1 mutant primary glioblastomas could be the endpoints of a 
disease following the same pathogenetic pathway. This hypothesis is supported by similar 
chromosomal and genetic aberration profiles in these two types of glioblastomas [13, 18] and might be 
taken into account by terming all IDH1 mutant glioblastomas secondary glioblastomas, thereby 
distinguishing them from the more common primary glioblastomas that are IDH1 wild type. However, 
there undoubtedly is a fraction of true secondary glioblastomas that progressed from a lower grade 
astrocytoma but lack IDH1 mutation, consistent with the lack of IDH1 mutations in approximately 20% 
of lower grade astrocytomas [1, 9, 22, 26]. These tumors argue against redefining the clinically 
established term of secondary glioblastoma. Another alternative might be to use the traditional 
designation “anaplastic astrocytoma WHO grade III” only for those anaplastic astrocytomas that carry 
an IDH1 mutation, while the term “anaplastic astrocytoma WHO grade IV” may be used for IDH1 wild 
type anaplastic astrocytomas. However, this designation is problematic as glioblastoma is traditionally 
regarded as the only type of astrocytic glioma corresponding to WHO grade IV. Furthermore, the 
WHO grade IV group would then cover a spectrum of malignant gliomas variably defined on 
histological and/or molecular features, and associated with different prognoses, i.e., IDH1 mutant and 
wild type glioblastomas, glioblastomas with oligodendroglial component or “anaplastic 
oligoastrocytoma WHO grade IV” [16], which show an intermediate prognosis between anaplastic 
oligoastrocytoma and glioblastoma [12], and IDH1 wild type anaplastic astrocytoma.  Thus, for the 
time being and for reasons of simplicity, we propose to continue using the conventional histological 
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terms of anaplastic astrocytoma and glioblastoma, respectively, supplemented by the IDH1 mutation 
status, and alert the physicians treating the patients concerning the prognostic implications of this 
molecular marker. 
In conclusion, we demonstrate that the IDH1 mutation status distinguishes anaplastic astrocytomas 
and glioblastomas into clinically meaningful prognostically distinct subgroups that possibly require 
different first-line treatment. Therefore, determination of IDH1 status is essential for a comprehensive 
neuropathological assessment of high-grade astrocytic gliomas and should be considered in the 
design and evaluation of future clinical trials. The differential distribution of IDH1 mutations across age 
groups largely explains the prognostic impact of age in high-grade astrocytoma patients. We propose 
to revise the current WHO classification of these tumors by inclusion of the IDH1 mutation status, 
which can be easily and reliably assessed by DNA sequencing or IHC.  
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table 1  
 
Patient characteristics 










Gender (male/female) 89/56 144/93 















KPS (≤ 70 / > 70) 10/127 51/181 
First-line treatment 
RT alone 
RT and CT (alkylating agents) 












Treatment at first recurrence 
RT alone 
RT and CT (alkylating agents) 
CT alone (alkylating agents) 















≤ 60 years 






2 (1.0%)  
MGMT promoter methylated 
≤ 60 years 
> 60 Years 
58/105 (55.2%) 
50 (47.6%) 




IDH1 and MGMT (N=338) 
IDH1 wt and MGMT meth - 
IDH1 wt and MGMT meth + 
IDH1 mut and MGMT meth - 













Abbreviations: RT = radiotherapy; CT = chemotherapy; wt = wild type; mut = mutated; meth - = 
unmethylated; meth + = methylated; A III = anaplastic astrocytoma WHO grade III; GBM = 
glioblastoma WHO grade IV 
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Model with main effects only Model: main effects and interactions with diagnosis 
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wt = wild type; mut = mutant; meth - =  unmethylated; meth + = methylated; A III = anaplastic 
astrocytoma WHO grade III; GBM = glioblastoma WHO grade IV 
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Age <= 60 (n=225)






Kaplan-Meier plots of the series of 382 anaplastic astrocytomas and glioblastomas showing the 
association with overall survival of histological WHO diagnosis (a), IDH1 mutation status (b), MGMT 
methylation status (c) and age (d). 























1 A III & MGMT meth - (n=47)
AIII & MGMT meth + (n=58)
GBM & MGMT meth - (n=123)






















1 A III & Age <= 60 (n=114)
A III & Age > 60 (n=31)
GBM & Age <= 60 (n=111)





Kaplan-Meier plot of the series of 338 anaplastic astrocytomas and glioblastomas showing the 
association with overall survival of the combination of WHO diagnosis and MGMT methylation status 
(a). Association of overall survival with the effect of the combination of WHO diagnosis and age are 
shown on the series of 382 patients (b). 
 
 

















1 A III & IDH mut (n=87)
A III & IDH wt (n=58)
GBM & IDH mut (n=17)
GBM & IDH wt (n=220)
p<0.0001
Age <= 60 Age > 60
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1 A III & IDH mut (n=78)
A III & IDH wt (n=36)
GBM & IDH mut (n=15)
GBM & IDH wt (n=96)
p<0.0001
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1 A III & IDH wt (n=22)








































A III & IDH mut (n=87)
A III & IDH wt (n=58)
GBM & IDH mut (n=17)

















Kaplan-Meier plot of the series of 382 anaplastic astrocytomas and glioblastomas patients showing 
the association of IDH1 status with overall survival (a) and progression-free survival (b). The same 
analysis regarding overall survival is shown for patients aged 60 years or younger (c). For patients 
older than 60 years, overall survival only for IDH1 wild type is shown (d). 















1 IDH wt & MGMT meth - (n=146)
IDH wt & MGMT meth + (n=115)
IDH mut & MGMT meth - (n=24)












Kaplan-Meier plot of the series of 338 anaplastic astrocytomas and glioblastomas showing the 
combined associations of IDH1 and MGMT status with overall survival. 
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Kaplan-Meier plots of OS of anaplastic astrocytoma and glioblastoma patients stratified according to 
histological diagnosis within the individual groups defined by the IDH1 mutation status in combination 
with the MGMT promoter methylation status. 
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Representative images of a primary glioblastoma with IDH1R132H mutation detected by 
immunohistochemistry with monoclonal antibody H09 (panel a, left), and of an anaplastic astrocytoma 
without IDH1 mutation (panel b, right). Original magnification x200. 
 
a  b
